TY - JOUR
T1 - Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. Reply
AU - Kirchhof, Paulus
AU - Schotten, Ulrich
AU - Zapf, Antonia
PY - 2023/12/14
Y1 - 2023/12/14
N2 - To the Editor: Kirchhof et al. (Sept. 28 issue)(1) found that anticoagulation with edoxaban did not reduce the incidence of cardiovascular death, stroke, or systemic embolism as compared with placebo among patients with atrial high-rate episodes (AHREs) detected by implantable devices. In the NOAH-AFNET 6 trial, the incidence of stroke, despite a median CHA(2)DS(2)-VASc score of 4 (on a scale from 0 to 9, with higher scores indicating a greater risk of stroke), was approximately 1% per patient-year. Among patients with atrial fibrillation, anticoagulation is recommended in those who have a minimum of two risk factors for stroke, specifically those . . .
AB - To the Editor: Kirchhof et al. (Sept. 28 issue)(1) found that anticoagulation with edoxaban did not reduce the incidence of cardiovascular death, stroke, or systemic embolism as compared with placebo among patients with atrial high-rate episodes (AHREs) detected by implantable devices. In the NOAH-AFNET 6 trial, the incidence of stroke, despite a median CHA(2)DS(2)-VASc score of 4 (on a scale from 0 to 9, with higher scores indicating a greater risk of stroke), was approximately 1% per patient-year. Among patients with atrial fibrillation, anticoagulation is recommended in those who have a minimum of two risk factors for stroke, specifically those . . .
U2 - 10.1056/NEJMc2312837
DO - 10.1056/NEJMc2312837
M3 - Comment/Letter to the editor
SN - 0028-4793
VL - 389
SP - 2302
EP - 2303
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 24
ER -